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INTRODUCTION
Nodal involvement is the most important prognostic fac-
tor in determining survival for patients with non-small cell
lung cancer (NSCLC) (1, 2). However, conventional lymph
node (LN) staging does not effectively reflect the wide dif-
ferences in LN involvement and patient survival, even in
patients classified within the same LN stage (3, 4). Further-
more, the characteristics of the mediastinal node (N2) are
rather heterogeneous. Consequently, several subclassifica-
tions with regard to LN involvement have been proposed.
Some investigators have also postulated the possible classifi-
cation of a subgroup of multiple station N2 patients who have
more unfavorable results compared to single station N2 pati-
ents with stage IIIA N2 NSCLC (3, 5-7). 
In this retrospective study, we attempted to clarify the
prognostic significance of multiple station N2 patients with
stage IIIA N2 lung cancer and to propose an adequate TNM
staging position for multiple station N2 disease by compar-
ing the survival of multiple station N2 patients to the sur-
vival patients with stage IIIB disease.
MATERIALS AND METHODS
Between 1990 and 2005, 1,326 patients underwent opera-
tions for non-small cell lung cancer at our institution. Of these
patients, 430 patients were diagnosed with either stage IIIA
N2 or stage IIIB disease by pathological examination. Patients
who received preoperative induction therapy (n=55) and those
who died within 1-month postoperatively (n=17) were excluded
from our study. Ultimately, a total of 358 patients were ana-
lyzed retrospectively. All patients underwent a thoracic com-
puted tomography (CT) scan. Clinical staging was determined
by bronchoscopy, chest CT, abdominal ultrasonogram, and
bone scans. Lymph nodes with a shortest diameter of 10 mm
or more were considered enlarged. The mediastinal node sta-
tus was assessed according to the system defined by Moun-
tain and Dresler (8). Systematic node dissection of the both
hilar and mediastinal lymph nodes was performed in all pati-
ents except for in 14 open and closure cases and 2 wedge resec-
tion cases. Six cycles of cisplatin-based adjuvant chemother-
apy were considered for all patients with stage II through stage
III from the early 1990s to 2004. After 2005, four cycles of
adjuvant chemotherapy were considered. Postoperative radio-
therapy was considered for patients who had N2-positive and
those who had positive resection margin. A Multiple station
N2 was defined as lymph node metastsis involving more than
one N2 station. Skip N2 was defined as metastasis-free hilar
and intrapulmonary lymph nodes. The pathological staging
was based on the 1997-TNM classification system (9). 
The group was comprised of 75 female and 283 male pati-
ents, with a median age of 61 yr (range, 31 to 78 yr). 262
patients were classified with stage IIIA N2 disease and 96
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The Prognostic Significance of Multiple Station N2 in Patients with
Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer
Mediastinal (N2) lymph node involvement is heterogenous with huge variation in
the extent and grouped together under stage IIIA. However, they showed a different
survival even in the same stage. We tried to determine the prognostic implication
of the multiple station N2 lymph node metastasis in stage IIIA N2 non-small cell
lung cancer (NSCLC). The survival of stage IIIA N2 was analyzed according to the
number of N2 station and their survival was compared with that of stage IIIB. In
stage IIIA N2 NSCLC, multivariate analysis indicated that multiple station N2 was
one of the independent prognostic factors for poor survival. The 5-yr survival of
multiple station N2 IIIA (20.4%) was lower than that of single station N2 IIIA (33.8%)
significantly (p=0.016). but when it was compared with that of stage IIIB (15.5%),
there was no difference. Therefore, we suggest that multiple station N2 should be
considered similar to stage IIIB disease with regard to predicting survival and accord-
ingly should receive a new position in the TNM staging system.
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patients were classified with stage IIIB disease. Among the
stage IIIB patients, 14 patients were open and closure cases.
Of these 14 patients, 10 cases did not have a proven patholog-
ical node stage. The median follow-up duration was 18.5
months (range, 1.2 to 184.2 months). All patients were fol-
lowed up until either death or the last follow-up date (Decem-
ber 31, 2006). The patient characteristics are summarized
in Table 1. 
The clinocopathological records of each patient with stage
IIIA N2 disease were examined for prognostic factors such as
age, sex, right or left side, type of surgical procedure (pneu-
monectomy or other procedure), histology, adjuvant che-
motherapy, tumor location (upper or lower), T stage, metastat-
ic node station (single or multiple station), and distribution
of metastatic nodes (skip N2 or non skip N2). The survival
rates of patients with stage IIIA N2 disease according to
significant prognostic factors were compared with those of
patients with stage IIIB disease. The Institutional Review
Board granted us permission to retrospectively review and
publish the patient records.
Statistical analysis
The association between variables was analyzed by either chi-
square or analysis of variances (ANOVA) tests. The duration
of survival was defined as the interval between the date of
surgery and either the date of death or the last follow-up date.
Survival rates were calculated using the Kaplan-Meier method,
and univariate analyses were performed using the log-rank
test. Multivariate analyses were performed by means of the
Cox proportional hazard model in variables that had p val-
ues less than 0.05 as determined by univariate analyses. A p
value less than 0.05 was considered significant. 
Variables No. of patients (%)
Age (median) 61 (31-78)
Sex
Male 283 (79.1)
Female 75 (20.9)
Type of resection
Pneumonectomy 187 (52.2)
Bilobectomy 45 (12.6)
Lobectomy 110 (30.7)
Other* 16 (4.5)
Histological subtype
Squamous cell 172 (48.0)
Adenocarcinoma 154 (43.0)
Other� 32 (9.0)
Pathologic tumor factor (pT)
pT1 38 (10.6)
pT2 166 (46.4)
pT3 72 (20.1)
pT4 82 (22.9)
Pathologic node factor (pN)�
pN0 26 (7.3)
pN1 14 (3.9)
pN2 292 (81.6)
pN3 16 (4.5)
Stage
IIIA 262 (73.2)
IIIB 96 (26.8)
N2 status in stage IIIA
Single N2 station 175 (66.8)
Multiple N2 station 87 (33.2)
Skip N2 in stage IIIA
Skip N2 97 (37.0)
Non-skip N2 165 (63.0)
Table 1. Clinical and pathological patient characteristics
*, Wedge resection in 2 patients and open and closure cases in 14
patients; �, large cell in 12, adenosquamous cell in 11, sarcomatoid
carcinoma in 3 and neuroendocrine tumor in 5; �, 10 open and closure
cases did not prove a pathological node factor.
Variables No. of 
patients 
p value
5-yr survival
rate (%)
Age (yr) 0.000
≤60 122 37.6
>60 140 21.4
Sex 0.023
Male 206 25.6
Female 56 41.6
Side 0.228
Right 160 22.3
Left 102 37.7
Operation 0.017
Pneumonectomy 141 22.3
Lobectomy or bilobectomy 121 37.7
Adjuvant chemotherapy 0.000
Yes 162 37.7
No 100 22.3
Histology 0.933
Adenocarcinoma 111 29.3
Others 151 28.8
Location 0.588
Upper 132 29.2
Middle or lower lobes 130 28.8
T stage 0.029
T1-2 194 32.4
T3 68 19.6
Clinical N status 0.012
cN0-1 116 36.0
cN2 146 23.6
Number of metastatic N2 stations 0.016
Single 175 33.8
Multiple 87 20.4
Skip N2 0.647
Non-skip 165 30.1
Skip 97 27.3
Table 2. Prognostic factors in stage IIIA N2 patients by univari-
ate analysis
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RESULTS
Overall survival rate
The overall 5-yr survival rates were 29.1% (95% confidence
interval [CI], 23.6 to 34.6%) for patients with stage IIIA
N2 disease and 15.5% (95% CI, 8.3 to 22.7%) for patients
with stage IIIB disease, with median survival durations of
21.6 months (95% CI, 17.5 to 25.6 months) and 15.8
months (95% CI, 11.0 to 20.6 months), respectively. This
difference in survival rates between the two patient groups
was statistically significant (p=0.011) (Fig. 1).
Prognostic significance of multiple station N2 in patients
with Stage IIIA N2 NSCLC
In stage IIIA N2 NSCLC, a univariate analysis using the
variables listed in Table 2 showed that the following factors
were significantly associated with poor outcome: age>60,
male, T3 factor, pneumonectomy, clinical N2, no adjuvant
chemotherapy, and multiple station N2. Using multivariate
analysis, we found that the independent unfavorable prog-
nostic factors were age>60, no adjuvant chemotherapy, and
multiple station N2 (Table 3).  
Survival rate according to the number of metastatic N2
stations 
We evaluated the effect of the number of metastatic N2
stations upon stage IIIA patient survival. The overall 5-yr
survival rates were 33.8% (95% CI, 26.8 to 40.8%) in sin-
gle station N2 patients and 20.4% (95% CI, 13.3 to 27.5%)
in multiple station N2 patients. The median survival times
in single station N2 and multiple station N2 patients were
26.4 months (95% CI, 20.3 to 32.5 months) and 18.2 months
(95% CI, 12.8 to 23.6months), respectively. The difference
was statistically significant (p=0.016). Furthermore, the sur-
vival rate of multiple station N2 patients in stage IIIA was
compared with the survival rate of stage IIIB patients, and
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Fig. 1. Overall survival curves of patients with stage IIIA N2 and
stage IIIB NSCLC.
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Fig. 2. Overall survival curves of patients with single station N2,
multiple station N2, and stage IIIB NSCLC.
Variables Hazard 
ratio
p
value
95% confi-
dence interval
Age (yr)
Age>60/age≤60 1.620 1.204-2.180 0.001
Sex
Male/female 1.320 0.907-1.921 0.147
Operation
Pneumonectomy/Lobectomy 1.328 0.976-1.807 0.071
or bilobectomy
Adjuvant chemotherapy
Yes/no 0.568 0.425-0.759 0.000
T stage
T3/T1-2 1.246 0.901-1.724 0.183
Clinical N status
cN2/cN0-1 1.204 0.885-1.637 0.238
Number of metastatic N2 stations
multiple/single 1.459 1.084-1.963 0.013
Table 3. Prognostic factors in N2 IIIA patients as determined
by Multivariate analysis
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we found no significant difference (p=0.585) (Fig. 2). 
Among the three groups, we found no difference in clinoco-
pathological variables such as age, sex, histopathology, tumor
size, number of resected LNs, or type of procedure performed
(except for the 14 open and closure cases).
DISCUSSION
Our results indicate that the multiple station N2 criteria
was one of the most important prognostic factors for poor
outcome after surgery in patients with stage IIIA N2 NSCLC.
Furthermore, we found that the multiple station N2 patients
with stage IIIA had a survival rate that was similar to the
stage IIIB patient survival rate. 
Several factors, such as the clinical N2 factor, the number
of metastatic N2 stations, T factor, tumor location, and skip
N2, have been reported as important prognostic factors in
patients with stage IIIA N2 cancer (7, 8, 10-13). Our unin-
variate analysis study showed that the significant unfavor-
able prognostic factors were age>60, male, T3 factor, pneu-
monectomy, clinical N2, no history of adjuvant chemother-
apy, and multiple station N2. Tumor location, histology, and
skip N2 status showed no prognostic significance in this
study. Furthermore, multivariate analysis confirmed that
multiple station N2, age >60, and no history of adjuvant
chemotherapy were significant, unfavorable prognostic fac-
tors. Several studies have shown that the number of metastat-
ic mediastinal LNs was an important prognostic factor (14-
16). Vansteenkiste and associates (17) reported that the 5-yr
survival for patients with single station N2 was 29.6% versus
20.8% for those with multiple station N2 (p=0.008). In our
study, the overall 5-yr survival rates were 33.8% in patients
with single station N2 and 20.4% in patients with multiple
station N2 (p=0.016). Besides the number of the metastatic
mediastinal LNs, the clinical N factor and skip metastatis
have also been considered prognostic factors in nodal factors
(13, 17). In our study, patients with skip metastasis did not
gain a survival benefit. In addition, clinical N2 patients
showed significantly unfavorable clinical outcomes on uni-
variate analysis but did not show a survival difference on to
multivariate analysis. With these results, the number of the
involved mediastinal LN stations can be recognized as a sin-
gle and reliable finding that indicates highly advanced N2
lung cancer. The role of adjuvant chemotherapy is consid-
ered controversial, but recent clinical trials have begun to
demonstrate the survival benefit of adjuvant chemotherapy
in select cases of NSCLC patients. Recent guidelines gener-
ally recommend adjuvant chemotherapy for patients with
completely resected stage IB through stage III NSCLC (18,
19). Our data support these results.
The current staging system for NSCLC has served us well
for a number of years. This system has helped us design a
treatment plan and discuss patient prognoses. However, the
most complex and unsatisfactory aspect of the current TNM
staging system is the method of assessing nodal disease. At
present, mediastinal node diseases are grouped together under
stage IIIA. However, there is a huge variation in the extent
of N2 disease, ranging from incidental nodal metastasis to
bulky multiple station, unresectable lymphadenopathy. Clear-
ly, these variations in stage IIIA N2 disease have far-reach-
ing implications with respect to both therapy and progno-
sis. Grouping all stage IIIA N2 disease into one stage is clearly
inappropriate. Furthermore, we need formal recognition for
a subclassification of stage IIIA N2 that considers variation.
Previous proposals have called for such a change in N2 dis-
ease classification (3, 5, 6). The previous subclassifications of
LN metastsis largely depended on the clinical node factor,
which were then decided by the size of the LNs, but these
classifications were not always correct because LN size is influ-
enced by several inflammatory processes, such as tuberculo-
sis and anthracosis (20, 21). In our study, clinical N2 did
not have a statistical significance. 
The number of metastatic mediastinal LNs is another
prognostic factor that has been considered a subclassifica-
tion indicator. Multiple station N2s have been accepted as
one of the most important prognostic factors (14-17). In our
study, multiple station N2 patients showed a significantly
poor outcome. These results confirm the relevance of sub-
classification based on the number of lymph node stations
involved. Therefore, stage IIIA N2 NSCLC patients should
be classified into two basically distinct patient subgroups:
single station N2 IIIA; multiple station N2 IIIA. 
Furthermore, the survival outcome in the present study
showed no difference between multiple station N2 IIIA and
stage IIIB patients. Andre and associates (5) reported that
the prognosis of clinical N2 and multiple station N2 patients
with stage IIIA disease was close to the prognosis of stage
IIIB disease patients. According to these results, we suggest
that multiple station N2 disease should be considered simi-
lar to stage IIIB disease for predicting patient survival and
therefore that multiple station N2 disease should receive a
new position in the TNM staging system.
In our study, we compared multiple station N2 with stage
IIIB for survival, but a better comparison might be between
multiple station N2 and N3 disease as a subgroup of stage
IIIB NSCLC. Pathologically proven N3 was not available in
surgically resected patients because these patients are not
usually indicated for surgery. In our institution, we treated
only 16 patients with N3 who underwent surgery and then
were proven to be N3 after the operation. Since this number
of patients was not enough to compare, we included all sur-
gically proven stage IIIB patients. 
In conclusion, multiple station N2 was one of the most
important single prognostic factors indicating a poor sur-
vival rate in pathological stage IIIA N2 NSCLC patients.
We found no difference in survival between multiple sta-
tion N2 stage IIIA and stage IIIB patients. Therefore, we
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suggest that multiple station N2 disease should be consid-
ered similar to stage IIIB disease for predicting patient sur-
vival and that these criteria should receive a new position in
a new TNM staging system.
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